Shares of Chinese robotics-component suppliers climbed after reports that Tesla teams arrived in the country to audit suppliers and place additional orders for its Optimus humanoid robot.
The stock gains reflect investor optimism around Tesla's humanoid robotics program. According to local reports, Tesla representatives conducted supplier audits in China, signaling plans to increase production volumes for Optimus.
The visits suggest Tesla is moving beyond prototype phases toward scaling manufacturing. Additional component orders indicate the company is preparing for higher-volume production runs, a critical step for commercial viability.
Chinese suppliers stand to benefit directly from increased orders. The audit process typically precedes volume commitments, making the visits a positive indicator for companies in the robotics supply chain.
Tesla has positioned Optimus as a long-term growth opportunity. The company previously announced plans to eventually produce more humanoid robots than cars. China's robotics ecosystem—including component manufacturers, integrators, and specialized suppliers—plays a central role in Tesla's supply chain strategy.
No official statement from Tesla has confirmed the audit details or production timelines.
A Republican-backed bill would empower rightsholders to obtain court orders forcing internet service providers, DNS providers, and VPN services to block access to foreign piracy websites.
The operator of GCash, the Philippines' largest mobile wallet, received stock exchange approval for an initial public offering valued at up to 92.3 billion pesos ($1.47 billion). The clearance removes the final regulatory obstacle for what would be a record IPO debut in the country.
SK Hynix has reached a labor agreement to pay half of all profit-sharing bonuses in cash, up from a previously proposed 40% cash allocation. The deal resolves a dispute between the South Korean chipmaker and its union.
Palantir Technologies has appointed Tom Watson, former UK Labour deputy leader, to an executive role in Britain amid mounting criticism of its proposed NHS contract.